Epics therapeutics

EPICS Therapeutics is a clinical-stage biotechnology company pioneering small-molecule modulators of RNA epigenetics for cancer treatment. The company focuses on the epitranscriptome, a process where specialized enzymes write, read, and erase marks on RNA that control how and when cells use genetic instructions. Its lead program, EP102, is a first-in-class potent and selective small-molecule inhibitor of METTL3, the enzyme responsible for installing the m6A mark on RNA, now advancing in clinical evaluation with patients with solid tumors. The pipeline also includes EP601, a GPR84 target in active preclinical development, and EP282, an FFAR2 target ready to enter Phase II clinical development for autoimmune disease treatment through the microbiome-immune axis. EPICS prioritizes cancers where METTL3 dysregulation intersects with DNA damage response pathways, including NSCLC, pancreatic cancer, ovarian cancer, and colorectal cancer. Founded in 2018 and headquartered in Charleroi, Belgium, the company has raised $24.7M in Series A funding from investors including SRIW, BNP Paribas Fortis, Sambrinvest, Investsud, Theodorus, Fund+, SFPI, and Capitaletcroissance.be.